<DOC>
	<DOCNO>NCT00858923</DOCNO>
	<brief_summary>Tulane University Health Sciences Center/Louisiana Community AIDS Research Center Program , New Orleans , LA seek patient HIV study . The purpose study test safety effectiveness experimental ultra-violet light device design reduce virus blood .</brief_summary>
	<brief_title>Safety Study HemoModulator System Treatment Patients With Human Immunodeficiency Virus ( HIV )</brief_title>
	<detailed_description>You may eligible : - You HIV - Your CD4 cell count great 400 - Your viral load great 10,00 copy - You yet qualify standard antiviral therapy ( HAART )</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Diagnosis HIV1 confirm positive ELISA Western Blot Subject yet eligible HAART Subject 's viral count prebaseline measure RTPCR 10,000 copy /ml Subject CD4+ count â‰¥ 400 cells/mm3 Subject 's prescreen EIA RIBA test proven negative Hepatitis C virus Female subject reproductive potential ( male sexual partner ) must agree use barrier device spermicide ( e.g. , condom , cervical cap , diaphragm ) primary form contraception , addition method use , treatment end study prevent pregnancy Subject take antiviral device pharmacologic treatment 2 month prior first schedule HemoModulator study treatment Subject agree receive antiviral device antiviral pharmacologic treatment ( include herbal remedy ) throughout 21week study period Subject weigh least 90 lb ( 40.9 kg ) study initiation Subject agree comply study protocol requirement include follow visit Day 60 study duration Subjects major illness ( e.g. , malignancy , renal failure , tuberculosis , porphyria , severe cardiac disease , severe neurological disease , Hepatitis C ) would prevent completion study bias efficacy assessment Subjects medical condition Investigator believe would make patient unable safely tolerate extracorporeal blood volume require procedure [ e.g. , severe cardiovascular disease , history congestive heart failure , severe anemia ( hemoglobin &lt; 90 g/L ) ] Subject porphyria cutanea tarda ( PCT ) , since PCT associate increased sensitivity light skin reaction redness , pain , swell blistering exposure ultraviolet light Subject clinically abnormal hemotologic chemistry laboratory value , define parameter test exceed Grade 1 ( DAIDS Table Grading Severity Adult Adverse Events , December 2004 ) Subject take steroid drug ( Estrogen Progesterone ) within 7 day prior study enrollment , may require medication course study participation Subject take drug list photosensitize Physician 's Desk Reference ( PDR ) within 7 day prior HemoModulator Treatment session Subjects habitually use excessive alcohol Subjects use illicit drug ongoing drug abuse problem Subjects acute systemic bacterial infection ( septicemia ) Subjects immunized influenza within 7 day prior study enrollment likely require immunization course study participation Subject currently participate another clinical investigation medical device , drug biologic , participate study within 3 month prior study enrollment Subject pregnant plan become pregnant within next twelve month ; lactate Subject clot deficiency Subject allergic heparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>Extracorporeal Photophoresis</keyword>
	<keyword>immuno-therapy</keyword>
	<keyword>treatment naive</keyword>
</DOC>